Results
1 -
10 of
101Clarithromycin co-administration does not increase irinotecan (CPT-11) toxicity in colorectal cancer patients, Cancer Chemotherapy and Pharmacology Evaluating the Potential for Delivery of Irinotecan via the Buccal Route: Physicochemical Characterization and In Vitro Permeation Assessment Across Porcine Buccal Mucosa, AAPS PharmSciTech Phase II study of bevacizumab and irinotecan as second-line therapy for patients with metastatic colorectal cancer previously treated with fluoropyrimidines, oxaliplatin, and bevacizumab, Cancer Chemotherapy and Pharmacology Distribution and quantification of irinotecan and its active metabolite SN-38 in colon cancer murine model systems using MALDI MSI, Analytical and Bioanalytical Chemistry Pre-treatment serum total bilirubin level as an indicator of optimal CPT-11 dosage, Cancer Chemotherapy and Pharmacology Retrospective comparative study of irinotecan and pegylated liposomal doxorubicin for platinum-resistant or -refractory epithelial ovarian and primary peritoneal carcinoma, Archives of Gynecology and Obstetrics A phase I study of irinotecan and pegylated liposomal doxorubicin in recurrent ovarian cancer (Tohoku Gynecologic Cancer Unit 104 study), Cancer Chemotherapy and Pharmacology Usefulness of one-point plasma SN-38G/SN-38 concentration ratios as a substitute for UGT1A1 genetic information after irinotecan administration, International Journal of Clinical Oncology Population pharmacokinetics of PEGylated liposomal CPT-11 (IHL-305) in patients with advanced solid tumors, European Journal of Clinical Pharmacology Preparation of Irinotecan-Loaded Folate-Targeted Liposome for Tumor Targeting Delivery and Its Antitumor Activity, AAPS PharmSciTech